Results 101 to 110 of about 315,915 (340)

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome [PDF]

, 2013
Background. Atypical forms of haemolytic uraemic syndrome (aHUS) include HUS caused by defects in the regulation of alternative complement pathway and HUS linked to neuraminidase- producing pathogens, such as Streptococcus pneumoniae. Increasing data
Szilágyi, Ágnes
core  

Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition

, 2017
Introduction IgA nephropathy (IgAN) is characterized by glomerular deposition of galactose-deficient IgA1 and complement proteins and leads to renal impairment.
Constantinou, N, Cook, HT, Hansen, AG, Lomax-Browne, HJ, Medjeral-Thomas, NR, Pickering, MC, Pusey, CD, Thiel, S, Troldborg, A, Willicombe, M   +9 more
core   +2 more sources

Complement C3 variant and the risk of age-related macular degeneration [PDF]

, 2007
Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors.
Armbrecht, AM, Bird, AC, Clayton, DG, Deary, IJ, Dhillon, B, Genetic Factors AMD Study G, Hayward, C, Khan, JC, Matharu, BK, Moore, AT, Morgan, J, Redmond, E, Sepp, T, Shahid, H, Thurlby, DA, Wright, AF, Yates, JRW   +16 more
core   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

A C3(H20) recycling pathway is a component of the intracellular complement system [PDF]

, 2017
An intracellular complement system (ICS) has recently been described in immune and nonimmune human cells. This system can be activated in a convertase-independent manner from intracellular stores of the complement component C3. The source of these stores
Botto, Bu, Hrishikesh S. Kulkarni, John P. Atkinson, Liszewski, M. Kathryn Liszewski, Michelle Elvington, Nickells, Paula Bertram, Seya, Singer, Vĕtvicka   +11 more
core   +2 more sources

Editorial: The complement system in autoimmunity

Frontiers in Immunology, 2022
Eveline Y. Wu, Eveline Y. Wu, Jessy J. Alexander, Shoichi Fukui, Shoichi Fukui, Shoichi Fukui, Shoichi Fukui   +6 more
doaj   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Alternative Complement Pathway Induction by ANCA [PDF]

The American Journal of Pathology, 2008
This Correspondence relates to "Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies" (Am J Pathol 2007, 170:52–64).
openaire   +2 more sources

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source